Advertisement
Screener

CASI PHARMACEUTICALS, INC. (CASIF) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

2.1 / 5 stars · 17/40 Roast Me

CASI PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

CASI PHARMACEUTICALS, INC. (CASIF) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.68% for the 12-month period ending 2025-12-31, per its 20-F filed 2026-05-15.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-05-15

Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, MinimumShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month
2025-12-313.68%
20-F · filed 2026-05-15
2024-12-313.41%
20-F · filed 2026-05-15
2023-12-313.45%
20-F · filed 2026-05-15
2023-05-123.45%
20-F · filed 2026-05-15
2022-12-311.98%
20-F · filed 2025-03-31
2021-12-310.72%
20-F · filed 2024-03-28
2020-12-310.31%
20-F · filed 2023-04-26